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Background Supplemental periconceptional folic acid
is recommended to reduce the risk of fetal neural tube
defects. A previous report indicated an elevated risk of
breast cancer and all cancer deaths in later life among
women randomised by alternate allocation to high-dose
(5 mg/day) folic acid in pregnancy compared with
placebo; however, ﬁndings were based on small
numbers of cases. Our aim was to extend the previous
analysis by including data from an additional 10 years of
follow-up.
Methods Records of participants in a large (n=2928)
trial of folate supplementation (5 or 0.2 mg folic acid, or
placebo) in pregnancy in the 1960s were linked to
central registries in Scotland. Unadjusted and adjusted
HRs were calculated for all-cause, cardiovascular, all
cancer and breast cancer mortality, and all cancer and
breast cancer morbidity. Analyses were done using (1)
data from the time of the previous linkage (2002) to
March 2013; and (2) data from 1980 to March 2013.
Results There was no evidence to suggest an excess
risk of morbidity or mortality in either supplementation
group compared with placebo for 2002–2013 and no
associations were seen for the full time period (1980–
2013).
Conclusions Findings from this extended follow-up
do not support our previous observation of an elevated
risk of mortality from breast cancer or all cancers in later
life among women who had taken 5 mg folic
acid/day during pregnancy. Furthermore, there were no
associations with risk of mortality from all-causes, all
cancers or cardiovascular disease.
INTRODUCTION
Folate (found in foods) or folic acid (synthetic
form) acts as a coenzyme in several single-carbon
transfers. These transfers lead to the synthesis of
purine nucleotide and deoxythymidylic acid which,
in turn, are essential for DNA and RNA synthesis.
It is well established that periconceptional folic acid
supplementation substantially reduces the risk of
neural tube defects in offspring.1–5 Several coun-
tries mandate the fortiﬁcation of food products
with folic acid (USA, Canada, etc6), whereas others
such as the UK advocate periconceptual supplemen-
tation (0.4 mg/day) until 12 weeks of gestation.7
The synthetic form of folic acid is nearly twice as
bioavailable as folate occurring naturally in food
and is more stable. Supplementation therefore leads
to relatively higher blood levels of the unmetabo-
lised form that remains in the blood for longer
than the natural form.8 The health consequences of
this are not completely understood and there are
concerns that fortiﬁcation and supplementation
could cause adverse effects, including masking of
vitamin B12 deﬁciency, neurotoxicity, drug interac-
tions, reduced zinc absorption and hypersensitivity
reactions.9
It has also been suggested that there is an associ-
ation between increased folic acid intake and
cancer promotion,9 but ﬁndings have been incon-
sistent. Evidence from epidemiological studies and
clinical trials suggests that there is an inverse rela-
tionship between folate intake and the incidence of
colorectal cancer,10–12 but a recent meta-analysis
did not ﬁnd any evidence of an effect of 5 years of
supplementation on overall and site-speciﬁc cancer
incidence.13 Some animal studies have shown that
supplementation increases the risk of experimental
carcinogenesis14 and an ecological study suggested
that mandatory folic acid fortiﬁcation in the
mid-1990s in the USA and Canada led to an
increase in rates of colorectal cancer.15 In a recent
follow-up of the aspirin/folate Polyp Prevention
Trial, in which folic acid was trialled as a
chemotherapeutic agent, there was an increased
risk of prostate cancer in men who had been rando-
mised to supplemental folic acid compared with
the placebo group.16 Evidence on the association of
folate supplementation with the incidence of breast
cancer is equally difﬁcult to interpret, and is
further complicated by studies reporting dietary
folate intake alone rather than total folate intake.17
A meta-analysis showed an inverse association
between dietary folate and risk of breast cancer in
case–control studies, but not prospective studies,
with a potential role for folate in attenuating the
increased risk of breast cancer associated with
alcohol consumption.18 The timing and dose of
folic acid may be critical in determining either
beneﬁcial or adverse effects on cancer risk and may
in part explain the conﬂicting results from both
epidemiological studies and clinical trials. The
inconsistency in ﬁndings could also potentially be
due to a ‘dual effect’ of folate: it has recently been
suggested that folate supplementation in people
with (undetected) precancerous cells may increase
the rate of malignant transformation of such
cells,19 possibly by causing aberrant DNA methyla-
tion,20 but in those without precancerous cells
folate it may confer a protective effect.
Folic acid supplementation may, however, be pro-
tective against cardiovascular disease (CVD): high
levels of homocysteine have been associated with
an increased risk of CVD, and folic acid
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supplementation is known to reduce homocysteine levels.21
However, in meta-analyses of randomised controlled trials, folic
acid supplementation was not shown to reduce the risk of CVD
among individuals with or without a prior history of vascular
disease or other predisposing factors.22–24 In trials that reported
the risk stratiﬁed by baseline homocysteine level, the risk of
CVD was increased in participants with higher homocysteine
levels and decreased in those with lower levels, suggesting that
folic acid may inﬂuence the progression of atherosclerotic
disease through pathways that are not dependent on the lower-
ing of homocysteine levels.23
The long-term effects of folic acid supplementation during
pregnancy on maternal mortality and morbidity in later life have
not been well studied. In a previous follow-up of a large
(n=2928) trial of folic acid supplementation in pregnancy from
the 1960s it was shown that randomisation to a high dose of
folic acid (5 mg/day, by alternate allocation) was associated with
a higher risk of mortality from cancer (HR=1.70, 95% CI 1.06
to 2.72) and possibly breast cancer speciﬁcally (HR=2.02, 95%
CI 0.88 to 4.72) in later life.25 However, the analyses were
based on relatively small numbers of cases (112 deaths due to
cancer and 31 to breast cancer), and the ﬁndings may have been
due to chance. The aim of the present study was to extend the
previous analysis by ascertaining the vital status and cause of
death up to March 2013, thereby adding about an additional
10 years of follow-up. The primary outcomes were all-cause, all
cancer, breast cancer and cardiovascular mortality; the second-
ary outcomes were all cancer and breast cancer morbidity.
MATERIALS AND METHODS
Participants, intervention and compliance
The parent study has been described in detail elsewhere.26–28
Brieﬂy, from June 1966 to June 1967, 3187 potentially eligible
women (women booking for antenatal care at <30 weeks gesta-
tion who were resident in Aberdeen, UK) were invited to enter
a double-blind randomised controlled trial to examine the
effects of folic acid supplementation on pregnancy outcomes. In
all, 2928 women were randomised by alternate allocation to
receive either 0.2 mg folic acid/day (n=466, 15.6%), 5 mg folic
acid/day (n=485, 16.6%) or a placebo (n=1977, 67.5%).
Compliance was assessed by self-report and by measurement of
folate status. In the placebo group, 1.9% reported that they had
not taken their tablets regularly, compared with 1.7% in the
group taking 0.2 mg folic acid and 3.2% in the group taking
5 mg. Prior to randomisation, serum folate concentrations were
similar in the three groups; a dose–response relationship was
seen after randomisation.28
Record linkage: morbidity and mortality data
For determination of the primary outcomes (all-cause, all
cancer, breast cancer and cardiovascular mortality), records of
the participants in this trial were linked to those held by the
Scottish NHS Central Registry in Edinburgh to provide data on
vital status and cause of death for those who had died from
January 1980 to March 2013. As per the previous follow-up,
the cause of death was assigned using the following codes: car-
diovascular mortality International Classiﬁcation of Diseases,
Ninth Revision (ICD-9) 410–414, 430–439 and ICD-10 120–
125, 160–169; all cancers ICD-9 140–208, ICD-10 C00–C97;
breast cancer ICD-9–174, ICD-10–C50). For determination of
the secondary outcomes (all-cancer and breast cancer morbid-
ity), the records of participants were also linked to the Scottish
Morbidity Records (SMR), speciﬁcally to the hospital admis-
sions (SMR01) and cancer registrations (SMR06), using both
deterministic matching on the Community Health Index (CHI)
numbers and probabilistic matching on names, dates of birth
and postcodes of residence. The SMR registers are held by the
Information and Services Division (ISD) of National Health
Service (NHS) Scotland.
Data analysis
Baseline data were summarised as means and SD (continuous
data) or number and percentage (categorical data). We calculated
unadjusted and adjusted HRs for the primary and secondary
outcomes using Stata v.13.1 (StataCorp, College Station, Texas,
USA). In contrast to our previous data linkage we do not have
data on mortality prior to 1980 as the costs of obtaining such
data were prohibitive. We are therefore unable to completely
replicate the ﬁndings that were presented in Charles et al.25 In
the present study, analyses for mortality and morbidity were
carried out for two time periods: 2002–2013 (to see if the ﬁnd-
ings reported previously were also seen in the ‘new’ time
period) and for the entire time period for which data in the
current linkage are available (ie, 1980–2013; the mean age of
the participants was approximately 73 years at the end of
follow-up). As per the previous analysis,25 we adjusted for
maternal age, smoking, height, weight, social class, parity and
gestational age. However, unlike the previous analysis, we were
unable to adjust for systolic blood pressure because we did not
have access to data on the full cohort.
RESULTS
The baseline characteristics of the women in the three treatment
groups were broadly comparable (table 1), with the exception of
Table 1 Baseline characteristics of the women enrolled in the







Age (years)* 26.0 (5.6) 25.8 (5.5) 25.5 (5.2)
Gestational age at booking
(weeks)
17.5 (5.3) 16.9 (4.8) 17.7 (5.6)
Weight at booking (kg)† 59.6 (9.5) 59.0 (8.9) 59.6 (9.1)
Height (cm)‡ 159.5 (5.9) 159.4 (6.4) 159.5 (6.1)
Smoked at booking, n (%)§ 840 (45.8) 188 (42.2) 203 (44.7)
Social class code, n (%)¶
I 122 (6.2) 31 (6.7) 34 (7.0)
II 219 (11.1) 44 (9.4) 49 (10.1)
IIIN 204 (10.3) 61 (13.1) 63 (13.0)
IIIM 768 (38.8) 170 (36.5) 146 (29.9)
IV 330 (16.7) 70 (15.0) 91 (18.8)
V 164 (8.3) 43 (9.2) 44 (9.1)
Undefined or armed forces 170 (8.6) 47 (10.1) 59 (12.2)
Parity, n (%)
0 734 (37.1) 198 (42.5) 196 (40.4)
1–3 904 (45.7) 216 (46.4) 224 (46.2)
≥4 339 (17.1) 52 (11.2) 65 (13.4)
Values are mean±SD.
Adapted with copyright permission from Charles et al.28
*Age available for 2868 (98%) women.
†Weight at booking available for 2813 (96.1%) women.
‡Height available for 2860 (97.7%) women.
§Smoking status at booking available for 2734 (93.4%) women.
¶Based on the husband’s or partner’s occupation at the time of delivery.
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a greater percentage of women having ≥4 pregnancies in the
placebo group, as discussed previously.28 For the ‘new’ time
period (2002–2013), there was no evidence to suggest an excess
risk of all-cause mortality, CVD mortality or breast cancer mor-
tality in either supplementation group (0.2 or 5 mg/day) com-
pared with placebo (table 2). There was a suggestion of a lower
risk of all cancer deaths in unadjusted (HR=0.36, 95% CI 0.16
to 0.83, p=0.02) and adjusted analyses (HR=0.43, 95% CI 0.19
to 1.00, p=0.05) for 5 mg folic acid/day compared with placebo
but not for 0.2 mg/day, but this ﬁnding was based on only six
deaths in the 5 mg/day group. No associations were observed
when looking at the full time period (1980–2013; table 3).
When the two supplementation groups were combined there was
no evidence of an association between folic acid supplementation
and mortality from all-causes, CVD, all cancers or breast cancer
(tables 2 and 3). There were no associations between folic acid
supplementation (at either dose) and morbidity from all cancers
or breast cancer (all associations p>0.05; tables 4 and 5).
DISCUSSION
In this extended follow-up of women who had participated in
the Aberdeen folate trial in the 1960s, we did not see any
strong evidence of an association between either dose of folic
acid taken during pregnancy and mortality from cancer or CVD
in later life.
In the previous analysis,25 there was a suggestion of an ele-
vated risk of mortality from all cancers, and possibly from
breast cancer speciﬁcally, among women who had received 5 mg
folic acid/day during pregnancy. For the present study, we con-
ducted separate analyses using only the newly acquired data
(to see if the ﬁndings reported previously were also seen in this
‘new’ time period), and using all data for the available time
period (which included data from the previous analysis plus the
additional years of follow-up). In contrast to our previous ﬁnd-
ings, in the ‘new’ time period there was a suggestion of a
decreased risk of all cancers among women in the high dose
folic acid group (5 mg/day). However, this ﬁnding was based on
a very small number of cases (n=6) and no associations were
seen for the full time period. Taken together, this suggests that
the previous ﬁndings in regards to an adverse effect on mortality
from all cancers and possibly breast cancer, and the current sug-
gestion of a potential protective effect on mortality from all
cancers, may be due to chance. Similar to our previous analysis,
we saw no effect of either dose of folic acid during pregnancy
on all-cause mortality or cardiovascular mortality in later life
when looking at either the ‘new’ time period alone or all data
that were available. There was no effect on all-cancer or breast
cancer morbidity in later life.
A ‘dual effect’ theory for the effects of folic acid has previ-
ously been proposed by Kim19 whereby folic acid in people
with undetected lesions at the time of supplementation may
promote the growth of such lesions, but there may be no (or
protective) effects in those without lesions. This could perhaps
explain the contrasting effects seen at differing time periods in
Table 2 Unadjusted and adjusted* HRs for mortality between 2002 and 2013 from all-causes, cardiovascular disease, cancer and breast cancer
in the groups given folic acid supplements in the Aberdeen folic acid supplementation trial, 1966–1967
n Unadjusted HR (95% CI; p value) p For trend Adjusted HR* (95% CI; p value) p For trend
Mortality risk in the two separate supplement groups
All-cause mortality
Placebo 163 1.00 0.46 1.00 0.89
0.2 mg folic acid 45 1.21 (0.86 to 1.67; 0.28) 1.27 (0.90 to 1.81; 0.17)
5 mg folic acid 33 0.79 (0.54 to 1.16; 0.23) 0.87 (0.58 to 1.31; 0.52)
Cardiovascular mortality
Placebo 37 1.00 0.18 1.00 0.17
0.2 mg folic acid 7 0.83 (0.37 to 1.86; 0.65) 1.00 (0.44 to 2.27; 1.00)
5 mg folic acid 15 1.63 (0.89 to 2.97; 0.11) 1.67 (0.86 to 3.26; 0.13)
All cancer deaths
Placebo 68 1.00 0.06 1.00 0.19
0.2 mg folic acid 20 1.27 (0.77 to 2.09; 0.35) 1.42 (0.84 to 2.39; 0.19)
5 mg folic acid 6 0.36 (0.16 to 0.83; 0.02) 0.43 (0.19 to 1.00; 0.05)
Breast cancer mortality
Placebo 16 1.00 0.28 1.00 0.31
0.2 mg folic acid 2 0.54 (0.12 to 2.34; 0.41) 0.52 (0.12 to 2.31; 0.39)
5 mg folic acid 2 0.51 (0.12 to 2.23; 0.37) 0.54 (0.12 to 2.41; 0.42)
Mortality risk in the two supplement groups combined
All-cause mortality
Placebo 163 1.00 1.00
Supplemented 78 0.99 (0.75 to 1.30; 0.93) 1.07 (0.80 to 1.43; 0.64)
Cardiovascular mortality
Placebo 37 1.00 1.00
Supplemented 22 1.25 (0.74 to 2.11; 0.41) 1.33 (0.75 to 2.35; 0.33)
All cancer deaths
Placebo 68 1.00 1.00
Supplemented 26 0.80 (0.51 to 1.26; 0.34) 0.91 (0.57 to 1.46; 0.70)
Breast cancer mortality
Placebo 16 1.00 1.00
Supplemented 4 0.52 (0.18 to 1.57; 0.25) 0.53 (0.17 to 1.62; 0.27)
*Adjusted for maternal age, smoking, height, weight, social class, parity and gestational age.
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our studies; however, the length of time of supplementation in
the present study may be too short for this theory to be rele-
vant. In addition, as noted earlier, the number of cases in the
‘new’ time period was too small to draw any meaningful
conclusions.
Pregnancy is likely to be to be a critical time for the determin-
ation of risk of subsequent breast cancer. To the best of our
knowledge, no other studies have undertaken a long-term
follow-up after folic acid supplementation in pregnancy, a time
during which breast tissue undergoes anatomical changes in
response to hormonal action and develops the ability to secrete
milk.29 Studies in animal models have provided consistent evi-
dence that the hormonal milieu of pregnancy is protective
against mammary tumours.30 In humans, however, the associa-
tions are more complex. Childbirth is followed by a short
period of increased risk,31 but early age at completion of ﬁrst
pregnancy, however, seems to be protective.32 The mechanisms
are poorly understood, but may involve the marked changes in
endogenous hormone concentrations, particularly oestrogen.33 34
Several studies have found dietary folate to be protective against
Table 3 Unadjusted and adjusted* HR’s for mortality between 1980 and 2013 from all-causes, cardiovascular disease, cancer, and breast
cancer in the groups given folic acid supplements in the Aberdeen folic acid supplementation trial, 1966–1967
n Unadjusted HR (95% CI; p value) p For trend Adjusted HR* (95% CI; p value) p For trend
Mortality risk in the two separate supplement groups
All-cause mortality
Placebo 289 1.00 0.88 1.00 0.22
0.2 mg folic acid 78 1.16 (0.91 to 1.49; 0.24) 1.23 (0.95 to 1.81; 0.12)
5 mg folic acid 70 0.97 (0.75 to 1.26; 0.82) 1.13 (0.86 to 1.48; 0.39)
Cardiovascular mortality
Placebo 69 1.00 0.34 1.00 0.22
0.2 mg folic acid 13 0.82 (0.45 to 1.48; 0.50) 0.92 (0.51 to 1.68; 0.80)
5 mg folic acid 23 1.35 (0.84 to 17; 0.21) 1.45 (0.87 to 2.41; 0.15)
All cancer deaths
Placebo 132 1.00 0.62 1.00 0.69
0.2 mg folic acid 36 1.17 (0.81 to 1.69; 0.41) 1.30 (0.89 to 1.90; 0.18)
5 mg folic acid 27 0.84 (0.55 to 1.27; 0.40) 1.00 (0.65 to 1.52; 0.99)
Breast cancer mortality
Placebo 36 1.00 0.77 1.00 0.61
0.2 mg folic acid 8 0.95 (0.44 to 2.04; 0.90) 0.98 (0.45 to 2.13; 0.96)
5 mg folic acid 10 1.14 (0.56 to 2.29; 0.72) 1.24 (0.61 to 2.51; 0.56)
Mortality risk in the two supplement groups combined
All-cause mortality
Placebo 289 1.00 1.00
Supplemented 148 1.06 (0.87 to 1.29; 0.60) 1.17 (0.95 to 1.44; 0.14)
Cardiovascular mortality
Placebo 69 1.00 1.00
Supplemented 36 1.09 (0.73 to 1.63; 0.67) 1.18 (0.77 to 1.80; 0.45)
All cancer deaths
Placebo 132 1.00 1.00
Supplemented 63 0.98 (0.73 to 1.33; 0.91) 1.13 (0.82 to 1.54; 0.45)
Breast cancer mortality
Placebo 36 1.00 1.00
Supplemented 18 0.99 (0.55 to 1.76; 0.97) 1.05 (0.58 to 1.89; 0.87)
*Adjusted for maternal age, smoking, height, weight, social class, parity and gestational age.
Table 4 Unadjusted and adjusted* HRs for morbidity between 2002 and 2013 from all cancer and breast cancer in the groups given folic acid
supplements in the Aberdeen folic acid supplementation trial, 1966–1967
n Unadjusted HR (95% CI; p value) p For trend Adjusted HR (95% CI; p value)* p For trend
All cancer morbidity
Placebo 134 1.00 0.46 1.00 0.88
0.2 mg folic acid 34 1.06 (0.73 to 1.54; 0.76) 1.18 (0.80 to 1.75; 0.41)
5 mg folic acid 27 0.82 (0.54 to 1.24; 0.35) 0.90 (0.59 to 1.39; 0.65)
Breast cancer morbidity
Placebo 34 1.00 0.77 1.00 0.98
0.2 mg folic acid 6 0.74 (0.31 to 1.76; 0.50) 0.86 (0.35 to 2.08; 0.74)
5 mg folic acid 8 0.96 (0.45 to 2.08; 0.93) 1.06 (0.46 to 2.44; 0.89)
*Adjusted for maternal age, smoking, height, weight, social class, parity and gestational age.
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breast cancer,35–37 but it is not known whether supplementary
folic acid in pregnancy modiﬁes this association.
Meta-analyses have provided conﬂicting information on the
role of long-term folic acid supplementation or dietary intakes
in non-pregnant participants on overall cancer incidence and
site-speciﬁc cancers. A recent meta-analysis of randomised trials
found no effect of 5 years of supplementation on the overall
cancer incidence or incidence of site-speciﬁc cancers (including
large intestine, prostate, lung and breast).13 With regard to
dietary intakes, a meta-analysis on folate intake reported an
association of higher intakes with a decreased risk of colorectal
cancer of 8–15% depending on the type of study.10 Another
meta-analysis reported a decreased risk of breast cancer with
increasing dietary folate intake (although no association was
seen with blood folate concentration).17 It is likely that the role
of folate in cancer is complex, and there may be differing
effects of natural (dietary) folate versus supplements. With
regard to CVD, meta-analyses of randomised controlled trials
also showed no effect of folic acid supplementation on the risk
of CVD in participants with or without a history of vascular
disease.23 24 Although the studies included in these
meta-analyses involved longer periods of supplementation (up
to 7 years) than the present study, the length of follow-up has
generally been much shorter (<7 years).
Our study has a number of strengths. The parent study was a
randomised controlled trial that included random allocation
(treatments were sequentially allocated but effectively
random38), adequate concealment and subjective and objective
evidence of good compliance, and the supplementation groups
were similar at baseline. In addition, to the best of our knowl-
edge this is the only long-term follow-up of women who had
taken two different doses of folic acid supplements during preg-
nancy. There are some limitations to this study. Despite an add-
itional 10 years of follow-up since our last data linkage, the
number of deaths was still relatively small, which resulted in
wide CIs around some of the hazard estimates. Exclusion of
deaths before 1980 is likely to have resulted in a small under-
estimation of mortality and morbidity, as would being conﬁning
the linkage to those participants still resident in Scotland. The
dose and timing of folate supplementation in the trial was dif-
ferent from current UK recommendations of 0.4 mg/day peri-
conceptually,7 which may limit the generalisability of the
ﬁndings to the present day population. Furthermore, the results
may not be generalisable to a wider UK population or to popu-
lations in other countries; this limitation may be ampliﬁed by
possible heterogeneity in the MTHFR gene, which may be
related to the risk of colorectal and other gastrointestinal
cancers.39 40
CONCLUSION
We did not ﬁnd any strong evidence to suggest an effect of
either dose of folic acid taken during pregnancy on mortality
from all-causes, cancer or CVD in later life, or on morbidity
from all cancer or breast cancer. Further data linkage studies
could be conducted in the future to conﬁrm whether this
remains the case with a longer period of follow-up and add-
itional deaths.
What is already known on this subject?
The long-term effects of folic acid supplementation during
pregnancy on maternal mortality in later life have not been well
studied. In a previous follow-up of a large trial of folic acid
supplementation in pregnancy from the 1960s it was shown
that randomisation to a high dose of folic acid (5 mg/day) was
associated with a higher risk of mortality from cancer and
possibly breast cancer speciﬁcally. However, the analyses were
based on relatively small numbers of cases and the ﬁndings
may have been due to chance.
What this study adds?
We did not ﬁnd any strong evidence to suggest an effect of
either dose of folic acid taken during pregnancy on mortality
from all-causes, cancer or cardiovascular disease in later life
with an extended follow-up time. Further data linkage studies
should be conducted in the future to conﬁrm whether this
remains the case with a longer period of follow-up and
additional deaths.
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